Covalently closed circular DNA, known as cccDNA, is the molecular reason hepatitis B virus (HBV) infections can last a lifetime even when antiviral drugs suppress the virus to undetectable levels in the blood. This tiny loop of viral DNA lodges inside the nucleus of infected liver cells, wraps itself in the cell’s own proteins, and quietly serves as the master template from which the virus copies all of its genes. Current standard-of-care drugs can block new virus production but cannot touch this reservoir, which is why researchers often call cccDNA elimination the “holy grail” of hepatitis B cure research. Understanding how cccDNA forms, how it survives, and what might finally destroy it is central to developing treatments that go beyond suppression and toward a genuine functional cure.
What cccDNA Actually Is
When HBV first infects a liver cell, the viral genome it delivers is not a neat, complete circle. It arrives as relaxed circular DNA (rcDNA), a partially double-stranded molecule with gaps and a protein covalently attached to one strand. Think of it as a rough draft. The cell’s own repair machinery then patches the gaps, removes the attached protein, and seals the ends, converting the rough draft into a polished, fully closed loop. That finished product is cccDNA.
Once formed, cccDNA does not just float freely in the nucleus. It gets packaged with histone proteins, the same spools that organize a cell’s own chromosomes, plus non-histone proteins including viral proteins HBc and HBx and various host factors. The result is a structure called the HBV minichromosome, which under an electron microscope looks like a “beads-on-a-string” arrangement, mimicking the cell’s own chromatin.1Cancer Biology & Medicine. Research progress in hepatitis B virus covalently closed circular DNA This disguise is part of what makes cccDNA so persistent: the cell treats it almost like its own genetic material, and the immune system has difficulty recognizing it as foreign.
How cccDNA Forms Step by Step
The journey from initial infection to a stable cccDNA molecule involves several stages, each dependent on different cellular machinery. After HBV binds to a liver cell and gets internalized, the viral capsid (the protein shell carrying the genome) needs to reach the nucleus. Capsids travel through the cell and dock at nuclear pore complexes, the gateways into the nucleus. A protein called nucleoporin 153 (Nup153) plays a key role here. Research has shown that HBV capsids bind directly to Nup153 with roughly 150-fold greater strength than the cell’s normal transport cargo, essentially hijacking the nuclear import system.2PLoS Pathogens. Nucleoporin 153 Arrests the Nuclear Import of Hepatitis B Virus Capsids in the Nuclear Basket The capsid then disassembles at the nuclear pore, releasing the rcDNA genome into the nucleus.
Once inside the nucleus, the rcDNA needs to be repaired and converted into cccDNA. This is where the cell’s own DNA repair enzymes get exploited. A screen of over 100 cellular DNA repair genes identified two host enzymes, DNA ligase 1 and DNA ligase 3, as critical players. Blocking these ligases or knocking down their function significantly reduced cccDNA production without affecting other steps of viral replication.3PLoS Pathogens. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation Another enzyme, flap endonuclease 1 (FEN1), was shown to be involved in trimming away the redundant flap structures on rcDNA. In lab experiments, combining FEN1 with a DNA polymerase and a DNA ligase was sufficient to convert rcDNA into functional cccDNA, while leaving out FEN1 and using only polymerase and ligase did not work efficiently.4PLoS Pathogens. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus
The picture that emerges is that HBV does not carry its own toolkit for making cccDNA. Instead, it depends entirely on the infected cell’s pre-existing DNA repair machinery. This dependency is both a vulnerability (those enzymes could theoretically be targeted) and a strength (those enzymes are essential to the cell, making them difficult to safely block in a patient).
How the cccDNA Pool Is Maintained
A single infected liver cell typically harbors only a handful of cccDNA molecules, often somewhere around two to five copies. Despite those modest numbers, the pool is remarkably stable. There are two known routes by which cccDNA levels can be replenished. First, newly made viral capsids containing rcDNA can be redirected back to the nucleus of the same cell rather than being exported and released. This intracellular recycling pathway lets the virus top off its cccDNA supply without needing to re-infect from outside. Second, virus particles released from one cell can infect neighboring cells, establishing fresh cccDNA through secondary infection.5PubMed Central. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels
However, the extent of cccDNA amplification appears to be self-limiting under normal conditions. In laboratory infection models, even when cells are exposed to very high amounts of virus, cccDNA levels plateau at a few copies per cell and do not keep climbing. Once established, those levels resist both reverse transcriptase inhibitors (which block new viral DNA synthesis) and entry inhibitors (which block new infection), indicating that the existing cccDNA molecules are inherently stable and do not need constant replenishment to persist.6JHEP Reports. cccDNA: New Insights Into Its Formation and Role This self-limiting behavior may be regulated by the virus itself. In duck hepatitis B virus, a related model, abolishing production of viral envelope proteins led to dramatically higher cccDNA amplification, suggesting that the normal secretion of virus particles acts as a brake on how many copies accumulate.7PubMed Central. Duck Hepatitis B Virus cccDNA Amplification Efficiency in Natural Infection Is Regulated by Virus Secretion Efficiency
How the Cell Controls cccDNA Transcription
Because cccDNA is organized into a minichromosome, its activity is governed by many of the same rules that control the cell’s own genes. Chemical modifications to the histone proteins wrapping cccDNA can switch it between active and silent states. Acetylation of histones generally loosens the chromatin and allows transcription, while methylation can tighten it and suppress gene expression. These epigenetic marks are not fixed; they shift in response to immune signaling, viral protein levels, and the overall state of the liver cell.8PubMed Central. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B
One of the more striking recent discoveries involves a host protein complex called SMC5/6. In an uninfected cell, SMC5/6 normally helps maintain chromosome structure. When HBV cccDNA appears in the nucleus, SMC5/6 recognizes it as foreign episomal DNA and clamps down on its transcription, acting as a built-in restriction factor. The virus fights back through its regulatory protein HBx, which tags SMC5/6 for destruction by the cell’s protein-disposal system (the proteasome). Once SMC5/6 is degraded, the brake on cccDNA transcription is released and viral gene expression ramps up.9PubMed Central. SMC5/6-Mediated Transcriptional Regulation of Hepatitis B Virus and Its Therapeutic Potential This tug-of-war between SMC5/6 and HBx is now a therapeutic target: drugs that prevent HBx from degrading SMC5/6 could, in theory, keep cccDNA permanently silenced even if they cannot eliminate it.
Host Defenses That Can Damage cccDNA
For a long time, cccDNA was viewed as essentially indestructible once formed. More recent work has identified at least one host pathway that can actively degrade it. A protein called hnRNPA2B1 recognizes unusual secondary structures (called G-quadruplexes) that form on cccDNA. When hnRNPA2B1 binds these structures, it recruits APOBEC3B, an enzyme that introduces deliberate mutations (specifically C-to-T and G-to-A changes) into the cccDNA sequence. These hypermutations corrupt the viral genome and trigger its decay.10PubMed Central. hnRNPA2B1 induces HBV cccDNA degradation by recruiting APOBEC3B This finding is significant because it shows the body does have at least some machinery capable of attacking cccDNA directly, not just suppressing its activity. Whether this pathway operates efficiently enough in chronic infection to meaningfully reduce the cccDNA reservoir, or whether HBV has evolved ways to blunt it, remains an open question.
Why cccDNA Is So Hard to Eliminate
The stability of cccDNA is the core obstacle to curing chronic hepatitis B. Antiviral drugs like tenofovir and entecavir, the current mainstay treatments, block the viral reverse transcriptase enzyme that makes new copies of viral DNA. They are very effective at suppressing virus in the blood, but they do not touch cccDNA sitting in the nucleus. In a study of patients co-infected with HIV and HBV who received tenofovir for a median of about 30 months, the estimated half-life of cccDNA was roughly 9 months overall, but this varied widely depending on the patient’s immune status: around 9 months for those who were HBeAg-positive and over 26 months for HBeAg-negative patients. Even with prolonged treatment, cccDNA remained detectable in every patient’s liver.11PubMed. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients
The behavior of cccDNA during antiviral therapy does not follow a simple, predictable curve. Short-term treatment studies suggest one rate of decline, while long-term data often show a much slower residual phase, as though a fraction of cccDNA molecules are particularly resistant to clearance.12PubMed Central. Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review This multi-phase decline likely reflects several overlapping processes: some cccDNA is lost when infected cells die and are replaced, some is diluted when cells divide, and some is actively degraded by immune mechanisms, but none of these processes is fast or thorough enough to clear the reservoir entirely.
Cell division offers a potential natural path to cccDNA loss. Unlike the cell’s own chromosomes, cccDNA lacks the molecular machinery for orderly distribution to daughter cells during mitosis. In a mouse model, forcing rapid liver cell proliferation (simulating liver regeneration) led to a dramatic hundred-fold drop in cccDNA per cell, driven by both dilution among daughter cells and outright loss of some molecules.13PubMed. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice Similar observations have been made in human liver cells transplanted into mice, where proliferation efficiently depleted cccDNA.14Gut. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo But there is a catch: in the related duck hepatitis B virus model, at least some cccDNA appeared to survive mitosis, with estimates suggesting roughly half of cccDNA molecules persisted through cell division.15Virology. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver And if intracellular recycling is still active, the virus can rebuild its cccDNA pool after each round of division. So cell turnover alone is unlikely to clear the infection unless new cccDNA formation is simultaneously blocked.
Why Measuring cccDNA Is Surprisingly Difficult
You might assume that detecting a specific DNA sequence would be straightforward with modern molecular biology tools. For cccDNA, it is anything but. Three properties conspire to make accurate measurement a persistent technical headache. First, cccDNA has the exact same nucleotide sequence as other forms of HBV DNA circulating in the cell, including the rcDNA precursor and various replicative intermediates, so standard sequence-based detection cannot distinguish between them. Second, cccDNA is present at very low copy numbers, just a few molecules per cell. Third, the tightly closed circular structure is unusually resistant to the heat denaturation steps used in standard PCR, making it behave unpredictably in amplification reactions.16PubMed Central. Approaches to quantifying hepatitis B virus covalently closed circular DNA
Researchers have developed various workarounds, each with trade-offs. Specialized DNA extraction methods (like the Hirt extraction) can enrich for cccDNA by removing other viral DNA forms, but they also retain a confounding molecule called protein-free relaxed circular DNA (pf-rcDNA), which looks like cccDNA to most assays. Enzymatic digestion with nucleases like T5 exonuclease can destroy non-cccDNA forms, but these treatments sometimes chew into cccDNA itself, leading to underestimates. Tissue preservation methods add another layer of complexity: samples stored in certain stabilizing solutions can suffer cccDNA damage when treated with nucleases.17PubMed Central. Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure These measurement challenges matter because clinical trials testing new HBV cure strategies need to prove that cccDNA has actually been reduced or eliminated, and unreliable assays could lead to false conclusions about a drug’s effectiveness.
Therapeutic Approaches Aimed at cccDNA
The search for drugs that can directly destroy or permanently silence cccDNA is one of the most active areas in hepatitis B research. Strategies broadly fall into three categories: preventing cccDNA from forming in the first place, destroying existing cccDNA, and silencing cccDNA transcription so it can no longer produce virus.
On the prevention front, capsid assembly modulators (CAMs) are a promising drug class already in clinical trials for their ability to disrupt the assembly of new viral capsids. Some CAMs also appear to affect cccDNA establishment. One compound, HAP_R01, was shown to perturb the structural integrity of incoming virus capsids, reducing their ability to deliver the viral genome to the nucleus and thereby inhibiting initial cccDNA formation. The concentrations needed for this effect were considerably higher than those needed to block new capsid assembly, but the dual mechanism is still attractive.18PubMed Central. A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection Other potent CAMs tested in primary human liver cells and differentiated HepaRG cells efficiently blocked both viral replication and de novo cccDNA establishment.19PubMed Central. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle
For destroying existing cccDNA, gene-editing tools like CRISPR-Cas9 have generated both excitement and caution. In cell-based experiments, CRISPR-Cas9 targeted to HBV sequences can efficiently cut cccDNA and reduce viral replication.20PubMed. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication In a mouse model carrying HBV cccDNA, injection of the CRISPR components lowered cccDNA levels and viral protein production. However, more recent work has tempered the optimism. When CRISPR-Cas9 cuts cccDNA, the broken ends do not always lead to destruction. Instead, the cell’s DNA repair machinery can rejoin the fragments, producing episomal HBV DNA variants that remain transcriptionally active.21PubMed Central. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants Even more sobering, one study concluded that CRISPR-Cas9-mediated inactivation of cccDNA, while effective at reducing viral markers, was not sufficient on its own to cure the infection.22Molecular Therapy: Nucleic Acids. cccDNA: New Insights Into Its Formation and Role The practical implication is that any cure strategy will probably need to combine multiple approaches rather than rely on a single magic bullet.
The SMC5/6 Pathway as a Drug Target
The discovery that SMC5/6 naturally silences cccDNA transcription, and that HBV’s HBx protein actively dismantles this defense, has opened an appealing therapeutic angle. If a drug could block HBx from degrading SMC5/6, the host cell’s own restriction machinery would keep cccDNA permanently silent. In effect, the virus would still be there, but it would be unable to produce any viral proteins or new copies of itself, a state sometimes called a “deep functional cure.” Several pharmaceutical companies are pursuing small molecules that interfere with the HBx-mediated destruction of SMC5/6, though these are still in early development.9PubMed Central. SMC5/6-Mediated Transcriptional Regulation of Hepatitis B Virus and Its Therapeutic Potential The appeal of this approach is that it works with a system the cell already has, rather than introducing an external editing tool like CRISPR that raises its own safety questions about off-target effects.
Lessons from the Duck Model
Much of what researchers know about cccDNA dynamics comes not from human HBV directly but from duck hepatitis B virus (DHBV), which infects duck liver cells in a closely analogous way. The duck model has been valuable precisely because ducks can be experimentally infected and their livers serially sampled in ways that are not feasible in human patients. DHBV studies were among the first to reveal that cccDNA amplification is regulated by viral secretion efficiency: when envelope protein production was knocked out, cccDNA levels surged, and inocula with different secretion capacities produced 10- to 100-fold differences in cccDNA accumulation in infected cells.7PubMed Central. Duck Hepatitis B Virus cccDNA Amplification Efficiency in Natural Infection Is Regulated by Virus Secretion Efficiency
The duck model has also given the most direct data on whether cccDNA survives cell division. In growing ducklings treated with the antiviral entecavir to block new cccDNA synthesis, liver mass increased 23-fold over the study period, yet cccDNA was not entirely eliminated. Mathematical analysis suggested that at least half of cccDNA molecules survived each round of hepatocyte mitosis, though low-level residual synthesis could not be completely ruled out.15Virology. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver If these findings translate to human HBV, they would mean that even aggressive strategies aimed at diluting cccDNA through liver cell turnover might leave a stubborn residual pool. Translation between species is always imperfect, but the duck model continues to generate hypotheses that guide human-focused research.
Why Importin β Matters for Empty Capsids
One less intuitive piece of the puzzle involves empty viral capsids, shells assembled without any genome inside. These are produced in large quantities during HBV replication, and for years their function was unclear. Research has shown that both empty capsids and free core protein can bind the nuclear transport factor importin β without needing the usual adaptor protein importin α.23PubMed Central. Importin β Binds Hepatitis B Virus Core Protein and Empty Cores This is unusual, as most cargo entering the nucleus requires both importin α and importin β working together. The ability of empty capsids to hijack nuclear transport through an alternative route raises the possibility that they play a role in modulating the intracellular environment, perhaps competing with genome-containing capsids for access to the nucleus or influencing host gene expression. Whether this matters for cccDNA dynamics specifically is still under investigation, but it adds complexity to the already intricate picture of how HBV interacts with the liver cell’s nuclear import system.